UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of Earliest Event Reported):
May 14, 2008
GERON
CORPORATION
(Exact
name of registrant as specified in its charter)
|
Delaware |
0-20859 |
75-2287752 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
230 CONSTITUTION DRIVE MENLO PARK, CALIFORNIA 94025 |
|
(Address of principal executive offices, including zip code) |
(650) 473-7700
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On May 14, 2008, Geron Corporation (the “Company”) publicly disseminated a press release announcing that the Company had received verbal notice today from the U.S. Food and Drug Administration (FDA) that the Company’s Investigational New Drug (IND) submission for GRNOPC1, the Company’s human embryonic stem cell-derived therapy for spinal cord injury, has been placed on clinical hold.
The foregoing description is qualified in its entirety by reference to the Company’s Press Release dated May 14, 2008, a copy of which is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
| (c) | Exhibits | ||
| 99.1 | Press release dated May 14, 2008. | ||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GERON CORPORATION |
|||
|
|
|||
|
Date: |
May 14, 2008 |
By: |
/s/ David L. Greenwood |
|
|
Name: |
David L. Greenwood |
|
|
Title: |
Executive Vice President, Chief Financial Officer |
||
EXHIBIT INDEX
|
Exhibit |
|
|
| 99.1 |
Press release dated May 14, 2008 |